Literature DB >> 3119718

Activated lymphocytes during acute Epstein-Barr virus infection.

B E Tomkinson1, D K Wagner, D L Nelson, J L Sullivan.   

Abstract

Activated lymphocytes, as identified by HLA-DR expression, associated with acute Epstein-Barr virus (EBV)-induced infectious mononucleosis (IM) were shown to be a heterogeneous population containing significantly elevated cytotoxic/suppressor (CD8) T cells, natural killer (CD16) cells and helper (CD4) T cells. CD8 T cells were the primary activated population representing 24.5% of the total lymphocyte population. The activated CD4 T cells and natural killer cells accounted for 6.7% and 3.5% of the total lymphocyte population, respectively. Analysis of serum soluble interleukin 2 receptors (IL-2R) demonstrated significantly (p less than 0.001) elevated levels in the serum of acute IM patients compared with normal controls. Elevated levels of serum IL-2R were correlated (r = 0.67) with increased percentages of Leu 2a+/HLA-DR+T cells (i.e., activated CD8 T cells). Patients with X-linked lymphoproliferative syndrome and virus-associated hemophagocytic syndrome, two syndromes associated with severe acute EBV infections, demonstrated the most dramatic increase in serum IL-2R levels. These data demonstrate that EBV is associated with intense immune stimulation and that during acute IM activated lymphocytes, other than the CD8 T cells, may contribute to the immune response to EBV.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3119718

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

1.  Expression of CD45R0 (UCHL1) by CD4+ and CD8+ T cells as a sign of in vivo activation in infectious mononucleosis.

Authors:  T Miyawaki; Y Kasahara; H Kanegane; K Ohta; T Yokoi; A Yachie; N Taniguchi
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

2.  Circulating mononuclear cells from euthyroid patients with thyroid-associated ophthalmopathy exhibit characteristic phenotypes.

Authors:  R S Douglas; A G Gianoukakis; R A Goldberg; S Kamat; T J Smith
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

3.  Epstein-Barr virus recombinants with specifically mutated BCRF1 genes.

Authors:  S Swaminathan; R Hesselton; J Sullivan; E Kieff
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

Review 4.  Virus-encoded superantigens.

Authors:  B T Huber; P N Hsu; N Sutkowski
Journal:  Microbiol Rev       Date:  1996-09

5.  Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus.

Authors:  B M Kerr; N Kienzle; J M Burrows; S Cross; S L Silins; M Buck; E M Benson; B Coupar; D J Moss; T B Sculley
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

Review 6.  X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology.

Authors:  D T Purtilo
Journal:  Springer Semin Immunopathol       Date:  1991

7.  Phenotypic characterization of CD8+ T cell populations in HIV disease and in anti-HIV immunity.

Authors:  K C Watret; J A Whitelaw; K S Froebel; A G Bird
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

Review 8.  Epstein-Barr virus infection and associated diseases in children. I. Pathogenesis, epidemiology and clinical aspects.

Authors:  V Schuster; H W Kreth
Journal:  Eur J Pediatr       Date:  1992-10       Impact factor: 3.183

9.  Elevated Le(y) antigen expression on T-lymphocytes in schizophrenic patients.

Authors:  M Kokai; I Hirata; M Adachi; N Hatotani; S Hakomori; T Tachibana
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

10.  Effects of virally expressed interleukin-10 on vaccinia virus infection in mice.

Authors:  M G Kurilla; S Swaminathan; R M Welsh; E Kieff; R R Brutkiewicz
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.